Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

ArkBio (爱科百发) Pre-IPO: Early Signs of Success for Recycled Assets

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shanghai Ark Biopharmaceutical / Equity Capital Markets

<ul>
<li>ArkBIo, a China-based near-commercial-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.</li>
<li>In our previous note, we looked at the company’s core products, AK0529 and AK3280. We also looked at the company’s pre-IPO investors and management team.</li>
<li>In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.</li>
</ul>


ArkBIo, a China-based near-commercial-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.
In our previous note, we looked at the company’s core products, AK0529 and AK3280. We also looked at the company’s pre-IPO investors and management team.
In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.


ArkBio (爱科百发) Pre-IPO: PHIP Update Shows RSV on Track, IPF Bar Rises